

Amendments to the Drawings

Please cancel figure 1.

Remarks

The pending claims are 14 and 16. Remaining claims 1-13, 15 and 17-27 have been withdrawn.

In the Office Action of June 3, 2003, claims 14 and 16 were indicated as allowable, and the Examiner requested correction of some inaccuracies in the specification in order to place the application in condition for allowance. In the Office Action of November 25, 2003, the Examiner indicated that Applicants' response filed September 22, 2003 did not place the application in condition for allowance, and the Examiner has requested clarification. The examiner also indicated that Applicants' September 22, 2003 response would not be entered.

Applicants enclose herewith a Power of Attorney from the assignee changing the correspondence address and authorizing Applicants' new additional attorney of record, designated below, to act on behalf of the assignee in this matter.

In further response to the Office Action mailed June 3, 2003 and to the Office communication mailed November 25, 2003, Applicants submit herewith a replacement computer readable form (CRF) Sequence Listing with 32 sequences. The replacement Sequence Listing is meant to identify the sequences that were previously and unintentionally unidentified in the specification. A copy of the diskette and paper copy are submitted herewith for the Examiner's convenience. Applicants again respectfully submit that no new matter is added by this amendment.

Applicants request deletion of Figure 1 because the sequence is incorrect. The sequence was supposed to be all nucleotides but it also contains amino acids and therefore cannot be properly represented in a Sequence Listing. Applicants respectfully submit that the figure is not material to the patentability of the instant invention, as currently claimed.


A substitute specification is again submitted herewith to correct typographical and grammatical errors, to include sequence identifiers, and to delete all references to Figure 1 and most references to SEQ ID NOs. 2 and 3. As noted, Applicants have removed references to Figure 1 because the sequence is incorrect. Applicants have removed most references to SEQ ID NOs. 2 and 3 because they are partial sequences and are not being prosecuted in this application.

The Examiner stated that the specification has text that is considered new matter. Applicants respectfully disagree and point out that the original text of the specification had words underlined, thus giving the appearance of being part of the amendment. Applicants have amended the text to remove the appearance that new matter was added. For example, the Examiner stated that "B. subtilis, Pseudomonas" was added. These organisms were included in the original application in underlined form. Applicants realize that this gave it the appearance of being added in the Version with Markings to Show Changes and have accordingly removed the underlining and instead italicized the words. The other section that the Examiner cites as new matter is at page 4, paragraph 9 of the Version with Markings to Show Changes beginning with "For the production in mammalian cells..." This section is not new matter but rather was removed from page 3, paragraph 6, last sentence and reinserted at page 4, paragraph 9 because the former paragraph was deleted and the sentence would lose its meaning if presented alone.

Should the Examiner have any further suggestions or observations that would facilitate further prosecution or allowance of this case, the Examiner is invited to contact Applicants' representative, designated below.

Applicants respectfully request placement of the present invention in condition of allowance, and passage to issuance.

Respectfully submitted,



Raymond Van Dyke
Reg. No. 34,746

December 22, 2003

Nixon Peabody LLP
Suite 900
401 9th Street
Washington D.C. 2004-2128
Tel: (202) 585-8250
Fax: (202) 585-8080